Characterization of ADC by LC/MS/MS
Antibody drug conjugates (ADCs) has become promising therapy for the treatment of cancers. Among all the ADCs
under developing, 2/3 of them are interchain cysteine linked ADCs. The ADCs are manufactured by partially reduce
the 4 pairs of interchain disulfide bond followed by conjugate cytotoxic payloads to the thiols, as a consequence, the
antibodies are linked with 0, 2, 4, 6, 8 drugs. The drug to antibody ratio (DAR) and the drug linking position are
important parameters that affect the therapeutic effects and need to be well characterized.
Recruiting Women for First-in-Human Trials: Tips for Success
Programs that need to include women in their FIH studies will find that successful enrollment of women is achievable; however, it requires a concerted effort, with the correct strategies and proper support. In the following pages, we explore the challenges in recruiting women for FIH studies and present a set of practices that have proven successful towards improving the recruitment rates of women for these studies.